Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma
We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemothera...
Gespeichert in:
| Veröffentlicht in: | Leukemia & lymphoma 2008-06, Vol.49 (6), p.1062-1073 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1073 |
|---|---|
| container_issue | 6 |
| container_start_page | 1062 |
| container_title | Leukemia & lymphoma |
| container_volume | 49 |
| creator | Till, Brian G. Gooley, Theodore A. Crawford, Nathan Gopal, Ajay K. Maloney, David G. Petersdorf, Stephen H. Pagel, John M. Holmberg, Leona Bensinger, William Press, Oliver W. |
| description | We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemotherapy with HyperCVAD with or without rituximab (±R) followed by ASCT in first complete or partial remission (CR1 PR1), 15 received CHOP (±R) followed by ASCT in CR1 PR1 and 20 received ASCT following disease progression. Estimates of overall and progression-free survival (PFS) at 3 years among patients transplanted in CR1 PR1 were 93% and 63% compared with 46% and 36% for patients transplanted with relapsed refractory disease, respectively. The hazard of mortality among patients transplanted with relapsed refractory disease was 6.09 times that of patients transplanted in CR1 PR1 (P = 0.006). Patients in the CHOP (±R) group had a higher risk of failure for PFS compared with patients in the HyperCVAD (±R) group, though the difference did not reach statistical significance (hazard ratio 3.67, P = 0.11). These results suggest that ASCT in CR1 PR1 leads to improved survival outcomes for patients with MCL compared to ASCT with relapsed refractory disease, and a HyperCVAD (±R) induction regimen may be associated with an improved PFS among patients transplanted in CR1 PR1. |
| doi_str_mv | 10.1080/10428190801923725 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_10428190801923725</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1080_10428190801923725</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-5293f00169d54bffe3a3720eaeffe163a52adf33cf6421447ccb3fdc7c8b61e3</originalsourceid><addsrcrecordid>eNp9kduKFDEQhhtR3IM-gDeSF2jNqbunUQRZVldY8GbvQ026Mp0lhyZJK_MIvrVpZlEXYa9Sqfr_L5WqpnnD6DtGd_Q9o5Lv2FhDNnIx8O5Zc84oH1suqXi-xZK3VSDPmouc7yml3djzl80Z28mO0747b35dG4O6kGhIQm9ztjGQXKCsmUCYiA3TqsuW1DP6WGZMsByr9mA9BlLzcS06etwIsJbo4iFWby7oiUbnSEkQ8uIgVOjGMTERX28OT3V39MscPbxqXhhwGV8_nJfN3Zfru6ub9vb7129Xn29b3VFe2o6PwlDK-nHq5L42L6D-nCJgjVkvoOMwGSG06SVnUg5a74WZ9KB3-56huGw-nbDLuvc4aQy1QaeWZD2ko4pg1eNKsLM6xB-KD_1IB14B7ATQKeac0PzxMqq2taj_1lI9b_999K_jYQ9V8PEksKHOx8PPmNykChxdTKYOUNusxFP8D4_sM4Irs4aE6j6uKdR5PtHdb5Qms2I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Till, Brian G. ; Gooley, Theodore A. ; Crawford, Nathan ; Gopal, Ajay K. ; Maloney, David G. ; Petersdorf, Stephen H. ; Pagel, John M. ; Holmberg, Leona ; Bensinger, William ; Press, Oliver W.</creator><creatorcontrib>Till, Brian G. ; Gooley, Theodore A. ; Crawford, Nathan ; Gopal, Ajay K. ; Maloney, David G. ; Petersdorf, Stephen H. ; Pagel, John M. ; Holmberg, Leona ; Bensinger, William ; Press, Oliver W.</creatorcontrib><description>We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemotherapy with HyperCVAD with or without rituximab (±R) followed by ASCT in first complete or partial remission (CR1 PR1), 15 received CHOP (±R) followed by ASCT in CR1 PR1 and 20 received ASCT following disease progression. Estimates of overall and progression-free survival (PFS) at 3 years among patients transplanted in CR1 PR1 were 93% and 63% compared with 46% and 36% for patients transplanted with relapsed refractory disease, respectively. The hazard of mortality among patients transplanted with relapsed refractory disease was 6.09 times that of patients transplanted in CR1 PR1 (P = 0.006). Patients in the CHOP (±R) group had a higher risk of failure for PFS compared with patients in the HyperCVAD (±R) group, though the difference did not reach statistical significance (hazard ratio 3.67, P = 0.11). These results suggest that ASCT in CR1 PR1 leads to improved survival outcomes for patients with MCL compared to ASCT with relapsed refractory disease, and a HyperCVAD (±R) induction regimen may be associated with an improved PFS among patients transplanted in CR1 PR1.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.1080/10428190801923725</identifier><identifier>PMID: 18452065</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; autologous stem cell transplantation ; CHOP ; Combined Modality Therapy ; Cyclophosphamide - therapeutic use ; Dexamethasone - therapeutic use ; Disease-Free Survival ; Doxorubicin - therapeutic use ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; HyperCVAD ; Lymphoma, Mantle-Cell - drug therapy ; Lymphoma, Mantle-Cell - therapy ; Male ; Mantle cell lymphoma ; Middle Aged ; Neoplasm Recurrence, Local - therapy ; non-Hodgkin lymphoma ; Prednisone - therapeutic use ; Remission Induction ; Rituximab ; Survival Rate ; Transplantation, Autologous ; Vincristine - therapeutic use</subject><ispartof>Leukemia & lymphoma, 2008-06, Vol.49 (6), p.1062-1073</ispartof><rights>2008 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-5293f00169d54bffe3a3720eaeffe163a52adf33cf6421447ccb3fdc7c8b61e3</citedby><cites>FETCH-LOGICAL-c502t-5293f00169d54bffe3a3720eaeffe163a52adf33cf6421447ccb3fdc7c8b61e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/10428190801923725$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/10428190801923725$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,59624,59730,60413,60519,61198,61233,61379,61414</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18452065$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Till, Brian G.</creatorcontrib><creatorcontrib>Gooley, Theodore A.</creatorcontrib><creatorcontrib>Crawford, Nathan</creatorcontrib><creatorcontrib>Gopal, Ajay K.</creatorcontrib><creatorcontrib>Maloney, David G.</creatorcontrib><creatorcontrib>Petersdorf, Stephen H.</creatorcontrib><creatorcontrib>Pagel, John M.</creatorcontrib><creatorcontrib>Holmberg, Leona</creatorcontrib><creatorcontrib>Bensinger, William</creatorcontrib><creatorcontrib>Press, Oliver W.</creatorcontrib><title>Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemotherapy with HyperCVAD with or without rituximab (±R) followed by ASCT in first complete or partial remission (CR1 PR1), 15 received CHOP (±R) followed by ASCT in CR1 PR1 and 20 received ASCT following disease progression. Estimates of overall and progression-free survival (PFS) at 3 years among patients transplanted in CR1 PR1 were 93% and 63% compared with 46% and 36% for patients transplanted with relapsed refractory disease, respectively. The hazard of mortality among patients transplanted with relapsed refractory disease was 6.09 times that of patients transplanted in CR1 PR1 (P = 0.006). Patients in the CHOP (±R) group had a higher risk of failure for PFS compared with patients in the HyperCVAD (±R) group, though the difference did not reach statistical significance (hazard ratio 3.67, P = 0.11). These results suggest that ASCT in CR1 PR1 leads to improved survival outcomes for patients with MCL compared to ASCT with relapsed refractory disease, and a HyperCVAD (±R) induction regimen may be associated with an improved PFS among patients transplanted in CR1 PR1.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>autologous stem cell transplantation</subject><subject>CHOP</subject><subject>Combined Modality Therapy</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Dexamethasone - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>HyperCVAD</subject><subject>Lymphoma, Mantle-Cell - drug therapy</subject><subject>Lymphoma, Mantle-Cell - therapy</subject><subject>Male</subject><subject>Mantle cell lymphoma</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>non-Hodgkin lymphoma</subject><subject>Prednisone - therapeutic use</subject><subject>Remission Induction</subject><subject>Rituximab</subject><subject>Survival Rate</subject><subject>Transplantation, Autologous</subject><subject>Vincristine - therapeutic use</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kduKFDEQhhtR3IM-gDeSF2jNqbunUQRZVldY8GbvQ026Mp0lhyZJK_MIvrVpZlEXYa9Sqfr_L5WqpnnD6DtGd_Q9o5Lv2FhDNnIx8O5Zc84oH1suqXi-xZK3VSDPmouc7yml3djzl80Z28mO0747b35dG4O6kGhIQm9ztjGQXKCsmUCYiA3TqsuW1DP6WGZMsByr9mA9BlLzcS06etwIsJbo4iFWby7oiUbnSEkQ8uIgVOjGMTERX28OT3V39MscPbxqXhhwGV8_nJfN3Zfru6ub9vb7129Xn29b3VFe2o6PwlDK-nHq5L42L6D-nCJgjVkvoOMwGSG06SVnUg5a74WZ9KB3-56huGw-nbDLuvc4aQy1QaeWZD2ko4pg1eNKsLM6xB-KD_1IB14B7ATQKeac0PzxMqq2taj_1lI9b_999K_jYQ9V8PEksKHOx8PPmNykChxdTKYOUNusxFP8D4_sM4Irs4aE6j6uKdR5PtHdb5Qms2I</recordid><startdate>200806</startdate><enddate>200806</enddate><creator>Till, Brian G.</creator><creator>Gooley, Theodore A.</creator><creator>Crawford, Nathan</creator><creator>Gopal, Ajay K.</creator><creator>Maloney, David G.</creator><creator>Petersdorf, Stephen H.</creator><creator>Pagel, John M.</creator><creator>Holmberg, Leona</creator><creator>Bensinger, William</creator><creator>Press, Oliver W.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>200806</creationdate><title>Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma</title><author>Till, Brian G. ; Gooley, Theodore A. ; Crawford, Nathan ; Gopal, Ajay K. ; Maloney, David G. ; Petersdorf, Stephen H. ; Pagel, John M. ; Holmberg, Leona ; Bensinger, William ; Press, Oliver W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-5293f00169d54bffe3a3720eaeffe163a52adf33cf6421447ccb3fdc7c8b61e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>autologous stem cell transplantation</topic><topic>CHOP</topic><topic>Combined Modality Therapy</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Dexamethasone - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>HyperCVAD</topic><topic>Lymphoma, Mantle-Cell - drug therapy</topic><topic>Lymphoma, Mantle-Cell - therapy</topic><topic>Male</topic><topic>Mantle cell lymphoma</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>non-Hodgkin lymphoma</topic><topic>Prednisone - therapeutic use</topic><topic>Remission Induction</topic><topic>Rituximab</topic><topic>Survival Rate</topic><topic>Transplantation, Autologous</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Till, Brian G.</creatorcontrib><creatorcontrib>Gooley, Theodore A.</creatorcontrib><creatorcontrib>Crawford, Nathan</creatorcontrib><creatorcontrib>Gopal, Ajay K.</creatorcontrib><creatorcontrib>Maloney, David G.</creatorcontrib><creatorcontrib>Petersdorf, Stephen H.</creatorcontrib><creatorcontrib>Pagel, John M.</creatorcontrib><creatorcontrib>Holmberg, Leona</creatorcontrib><creatorcontrib>Bensinger, William</creatorcontrib><creatorcontrib>Press, Oliver W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Till, Brian G.</au><au>Gooley, Theodore A.</au><au>Crawford, Nathan</au><au>Gopal, Ajay K.</au><au>Maloney, David G.</au><au>Petersdorf, Stephen H.</au><au>Pagel, John M.</au><au>Holmberg, Leona</au><au>Bensinger, William</au><au>Press, Oliver W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>2008-06</date><risdate>2008</risdate><volume>49</volume><issue>6</issue><spage>1062</spage><epage>1073</epage><pages>1062-1073</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemotherapy with HyperCVAD with or without rituximab (±R) followed by ASCT in first complete or partial remission (CR1 PR1), 15 received CHOP (±R) followed by ASCT in CR1 PR1 and 20 received ASCT following disease progression. Estimates of overall and progression-free survival (PFS) at 3 years among patients transplanted in CR1 PR1 were 93% and 63% compared with 46% and 36% for patients transplanted with relapsed refractory disease, respectively. The hazard of mortality among patients transplanted with relapsed refractory disease was 6.09 times that of patients transplanted in CR1 PR1 (P = 0.006). Patients in the CHOP (±R) group had a higher risk of failure for PFS compared with patients in the HyperCVAD (±R) group, though the difference did not reach statistical significance (hazard ratio 3.67, P = 0.11). These results suggest that ASCT in CR1 PR1 leads to improved survival outcomes for patients with MCL compared to ASCT with relapsed refractory disease, and a HyperCVAD (±R) induction regimen may be associated with an improved PFS among patients transplanted in CR1 PR1.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>18452065</pmid><doi>10.1080/10428190801923725</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 2008-06, Vol.49 (6), p.1062-1073 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_10428190801923725 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Adult Aged Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols - therapeutic use autologous stem cell transplantation CHOP Combined Modality Therapy Cyclophosphamide - therapeutic use Dexamethasone - therapeutic use Disease-Free Survival Doxorubicin - therapeutic use Female Hematopoietic Stem Cell Transplantation Humans HyperCVAD Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - therapy Male Mantle cell lymphoma Middle Aged Neoplasm Recurrence, Local - therapy non-Hodgkin lymphoma Prednisone - therapeutic use Remission Induction Rituximab Survival Rate Transplantation, Autologous Vincristine - therapeutic use |
| title | Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A18%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20remission%20status%20and%20induction%20chemotherapy%20regimen%20on%20outcome%20of%20autologous%20stem%20cell%20transplantation%20for%20mantle%20cell%20lymphoma&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Till,%20Brian%20G.&rft.date=2008-06&rft.volume=49&rft.issue=6&rft.spage=1062&rft.epage=1073&rft.pages=1062-1073&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.1080/10428190801923725&rft_dat=%3Cinformahealthcare_cross%3E10_1080_10428190801923725%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18452065&rfr_iscdi=true |